
BIOSYNEX COVID-19 Ag BSS

(E



A rapid test for the qualitative detection of COVID-19 antigen in swab or aspirate specimens.

- Simple
 Using nasopharyngeal swab or aspirate samples
 Only few steps
- Rapid detection of COVID 19 antigens
 Results in 10 minutes
- Convenient and easy to use
 Performed directly alongside the patient or in the laboratory
 The kit can be stored at 2-30°C



BIOSYNEX COVID-19 Ag BSS




- COVID-19 is a disease caused by a novel coronavirus (CoV) SARS-CoV-2 also known as 2019-nCoV.
- The most common symptoms of COVID-19 are fever, tiredness, and dry cough. Some people become infected but don't develop any symptoms and don't feel unwell.
- · In order to facilitate patient management and to identify infected individuals, especially those at risk of complications, it is essential to be able to rapidly detect the presence of CoV-2-SARS.
- The BIOSYNEX COVID-19 Ag BSS is a rapid chromatographic immunoassay for the qualitative detection of **COVID-19** antigen, in only 10 minutes, using a nasopharyngeal swab or nasal aspirate sample.

PROCEDURE – for nasopharyngeal swabs




Insert the swab horizontally 3 cm inside the nasal cavity.


http://youtu.be/DVJNWefmHjE for more information on the nasopharyngeal swab collection



Empty a single-dose of extraction reagent into an extraction tube



Discharge the swab into the extraction tube by **rotating** the swab for approximately 10 seconds



Screw on the cap of the extraction tube and place 3 drops of the solution in well S.






Read the result at 10 minutes. Do not read after 20 minutes.

RESULTS





PERFORMANCE*

Sensitivity: 89.1% **Specificity:** 99,2%

*Compared to PCR reference method. Refer to the instructions for use for more information.


MATERIALS INCLUDED

BIOSYNEX COVID-19 Ag BSS

Ref. SW40006

Contains:

- Test cassettes
- Extraction reagents
- Extraction tubes
- **Droppers**
- Sterile Swabs
- Workstation
- Package insert



RIRI IOGRAPHY

- 1. World Health Organization (WHO). WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Beijing: WHO; 9 Jan 2020.
- 2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, International Journal of Antimicrobial Agents, March 2020
- 3. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 11, 2020
- 4. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol 2020; published online Jan 16.
- 5. Chen, N; Zhou, M; Dong, X; Qu, J; Gong, F; Han, Y; Qiu, Y; Wang, J; Liu, Y; Wei, Y; Xia, J; Yu, T; Zhang, X; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223): 507-513
- 6. Williams, KM, Jackson MA, Hamilton M. (2002) Rapid Diagnostic Testing for URIs in Children; Impact on Physician Decision Making and Cost. Infec. Med. 19(3): 109-111



Distributie in Nederland



Mediphos Medical Supplies BV Industrieweg 12B 6871KA Renkum

info@mediphos.com



Rue de Romont 29 - 31 CH-1700 FRIBOURG Switzerland